Seroconversion Rate After Primary Vaccination with Two Doses of BNT162b2 Versus MRNA-1273 in Solid Organ Transplant Recipients: a Systematic Review and Meta-analysis

Overview

Journal Nephrol Dial Transplant

Publisher Oxford University Press

Specialties General Surgery
Nephrology

Date 2022 May 11

PMID 35544087

Authors

Arno Verleye

Veerle Wijtvliet

Steven Abrams

Rachel Hellemans

Rania Bougrea

Annick Massart

Lissa Pipeleers

Karl Martin Wissing

Kevin K Arien

Benedicte Y De Winter

Pierre Van Damme

Daniel Abramowicz

Kristien J Ledeganck

Affiliations

Soon will be listed here.

Abstract

Background: In the general population, the seroconversion rate after primary vaccination with two doses of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA (mRNA) vaccine reaches nearly 100%, with significantly higher antibody titers after mRNA-1273 vaccination compared to BNT162b2 vaccination. Here we performed a systematic review and meta-analysis to compare the antibody response after two-dose mRNA-1273 versus BNT162b2 vaccination in solid organ transplant (SOT) recipients.

Methods: A systematic literature review was performed using PubMed, Web of Science and the Cochrane Library and original research papers were included for a meta-analysis to calculate vaccine-specific seroconversion rates for each of the mRNA vaccines. Next, the pooled relative seroconversion rate was estimated.

Results: Eight studies that described the development of antibodies against receptor-binding domain (RBD) and/or spike protein were eligible for meta-analysis. Two of these studies also reported antibody titers. The meta-analysis revealed lower seroconversion rates in SOT recipients vaccinated with two doses of BNT162b2 {44.3% [95% confidence interval (CI) 34.1-54.7]} as compared with patients vaccinated with two doses of mRNA-1273 [58.4% (95% CI 47.2-69.2)]. The relative seroconversion rate was 0.795 (95% CI 0.732-0.864).

Conclusions: This systematic review and meta-analysis indicates that in SOT recipients, higher seroconversion rates were observed after vaccination with mRNA-1273 compared with BNT162b2.

Citing Articles

Humoral immunity to SARS-CoV-2 in kidney transplant recipients and dialysis patients: IgA and IgG patterns unraveled after SARS-CoV-2 infection and vaccination.

De Bouver C, Bouziotis J, Wijtvliet V, Arien K, Marien J, Heyndrickx L Virol J. 2024; 21(1):138.

PMID: 38872127 PMC: 11170792. DOI: 10.1186/s12985-024-02410-1.

Multi-omics Approach in Kidney Transplant: Lessons Learned from COVID-19 Pandemic.

Mizuno H, Murakami N Curr Transplant Rep. 2023; 10(4):173-187.

PMID: 38152593 PMC: 10751044. DOI: 10.1007/s40472-023-00410-8.

Impact of SARS-CoV-2 Infection on Humoral and Cellular Immunity in a Cohort of Vaccinated Solid Organ Transplant Recipients.

Ayala-Borges B, Escobedo M, Egri N, Herrera S, Crespo M, Mirabet S Vaccines (Basel). 2023; 11(12).

PMID: 38140248 PMC: 10747916. DOI: 10.3390/vaccines11121845.

Susceptibility to SARS-CoV-2 Infection and Immune Responses to COVID-19 Vaccination Among Recipients of Solid Organ Transplants.

Subramanian V J Infect Dis. 2023; 228(Suppl 1):S34-S45.

PMID: 37539762 PMC: 10401623. DOI: 10.1093/infdis/jiad152.

Serological Responses after a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.

Mu Y, Wu H, Jiang Z, Liu K, Xue X, Zhang W Vaccines (Basel). 2023; 11(7).

PMID: 37514946 PMC: 10385971. DOI: 10.3390/vaccines11071130.

References

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J . Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003; 73(9):712-6. DOI: 10.1046/j.1445-2197.2003.02748.x. View

Tenforde M, Self W, Adams K, Gaglani M, Ginde A, McNeal T . Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. 2021; 326(20):2043-2054. PMC: 8569602. DOI: 10.1001/jama.2021.19499. View

Kantauskaite M, Muller L, Kolb T, Fischer S, Hillebrandt J, Ivens K . Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients. Am J Transplant. 2021; 22(2):634-639. PMC: 8653081. DOI: 10.1111/ajt.16851. View

Ollila T, Lu S, Masel R, Zayac A, Paiva K, Rogers R . Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease. JAMA Oncol. 2021; 7(11):1714-1716. PMC: 8358793. DOI: 10.1001/jamaoncol.2021.4381. View

Dickerman B, Gerlovin H, Madenci A, Kurgansky K, Ferolito B, Figueroa Muniz M . Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans. N Engl J Med. 2021; 386(2):105-115. PMC: 8693691. DOI: 10.1056/NEJMoa2115463. View

Wang L, Davis P, Kaelber D, Volkow N, Xu R . Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period. JAMA. 2022; 327(7):678-680. PMC: 8778597. DOI: 10.1001/jama.2022.0210. View

Quiroga B, Soler M, Ortiz A, Martinez Vaquera S, Jarava Mantecon C, Useche G . Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study. Nephrol Dial Transplant. 2021; 37(10):1868-1878. PMC: 8767866. DOI: 10.1093/ndt/gfab313. View

Boyarsky B, Werbel W, Avery R, Tobian A, Massie A, Segev D . Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021; 325(21):2204-2206. PMC: 8100911. DOI: 10.1001/jama.2021.7489. View

Markewitz R, Pauli D, Dargvainiene J, Steinhagen K, Engel S, Herbst V . The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273. Clin Microbiol Infect. 2021; 28(5):701-709. PMC: 8450229. DOI: 10.1016/j.cmi.2021.09.006. View

10.

Lacson Jr E, Argyropoulos C, Manley H, Aweh G, Chin A, Salman L . Immunogenicity of SARS-CoV-2 Vaccine in Dialysis. J Am Soc Nephrol. 2021; 32(11):2735-2742. PMC: 8806103. DOI: 10.1681/ASN.2021040432. View

11.

Juthani P, Gupta A, Borges K, Price C, Lee A, Won C . Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect Dis. 2021; 21(11):1485-1486. PMC: 8423430. DOI: 10.1016/S1473-3099(21)00558-2. View

12.

Stumpf J, Siepmann T, Lindner T, Karger C, Schwobel J, Anders L . Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur. 2021; 9:100178. PMC: 8299287. DOI: 10.1016/j.lanepe.2021.100178. View

13.

Garcia P, Anand S, Han J, Montez-Rath M, Sun S, Shang T . COVID-19 Vaccine Type and Humoral Immune Response in Patients Receiving Dialysis. J Am Soc Nephrol. 2021; 33(1):33-37. PMC: 8763174. DOI: 10.1681/ASN.2021070936. View

14.

Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L . Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. JAMA. 2021; 326(15):1533-1535. PMC: 8406205. DOI: 10.1001/jama.2021.15125. View

15.

Yau K, Chan C, Abe K, Jiang Y, Atiquzzaman M, Mullin S . Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. CMAJ. 2022; 194(8):E297-E305. PMC: 9053976. DOI: 10.1503/cmaj.211881. View

16.

Debska-Slizien A, Muchlado M, Slizien Z, Kubanek A, Piotrowska M, Dabrowska M . Significant humoral response to mRNA COVID-19 vaccine in kidney transplant recipients with prior exposure to SARS-CoV-2: the COViNEPH Project. Pol Arch Intern Med. 2021; 132(1). DOI: 10.20452/pamw.16142. View

17.

Yi S, Moore L, Eagar T, Graviss E, Nguyen D, Ibrahim H . Risk Factors Associated With an Impaired Antibody Response in Kidney Transplant Recipients Following 2 Doses of the SARS-CoV-2 mRNA Vaccine. Transplant Direct. 2021; 8(1):e1257. PMC: 8670582. DOI: 10.1097/TXD.0000000000001257. View

18.

Payne R, Longet S, Austin J, Skelly D, Dejnirattisai W, Adele S . Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell. 2021; 184(23):5699-5714.e11. PMC: 8519781. DOI: 10.1016/j.cell.2021.10.011. View

19.

Richardson W, Wilson M, Nishikawa J, Hayward R . The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995; 123(3):A12-3. View

20.

Schoenmaker L, Witzigmann D, Kulkarni J, Verbeke R, Kersten G, Jiskoot W . mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm. 2021; 601:120586. PMC: 8032477. DOI: 10.1016/j.ijpharm.2021.120586. View